- Home
- LNZA vs ESPR Comparison
LNZA vs ESPR Comparison
Compare LNZA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- ESPR
- Stock Information
- Founded
- LNZA 2005
- ESPR 2008
- Country
- LNZA United States
- ESPR United States
- Employees
- LNZA N/A
- ESPR N/A
- Industry
- LNZA Major Chemicals
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- LNZA Industrials
- ESPR Health Care
- Exchange
- LNZA Nasdaq
- ESPR Nasdaq
- Market Cap
- LNZA 65.7M
- ESPR 202.2M
- IPO Year
- LNZA N/A
- ESPR 2013
- Fundamental
- Price
- LNZA $0.28
- ESPR $1.17
- Analyst Decision
- LNZA Hold
- ESPR Buy
- Analyst Count
- LNZA 2
- ESPR 6
- Target Price
- LNZA $2.00
- ESPR $6.50
- AVG Volume (30 Days)
- LNZA 2.3M
- ESPR 3.2M
- Earning Date
- LNZA 08-07-2025
- ESPR 08-11-2025
- Dividend Yield
- LNZA N/A
- ESPR N/A
- EPS Growth
- LNZA N/A
- ESPR N/A
- EPS
- LNZA N/A
- ESPR N/A
- Revenue
- LNZA $48,831,000.00
- ESPR $259,574,000.00
- Revenue This Year
- LNZA $58.17
- ESPR $4.07
- Revenue Next Year
- LNZA $10.92
- ESPR N/A
- P/E Ratio
- LNZA N/A
- ESPR N/A
- Revenue Growth
- LNZA N/A
- ESPR 12.99
- 52 Week Low
- LNZA $0.14
- ESPR $0.69
- 52 Week High
- LNZA $2.74
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- LNZA 50.36
- ESPR 61.04
- Support Level
- LNZA $0.25
- ESPR $0.95
- Resistance Level
- LNZA $0.33
- ESPR $1.06
- Average True Range (ATR)
- LNZA 0.04
- ESPR 0.08
- MACD
- LNZA -0.00
- ESPR -0.00
- Stochastic Oscillator
- LNZA 37.63
- ESPR 81.48
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.